Updates in Advanced Ovarian Cancer Care

Dr. Kais Razzouk, Pr. Rafii Arash, Dr Justine Cagnat





What is Ovarian Cancer?

 The most common type of Ovarian Cancer that starts from <u>epithelial</u> <u>cells –gland forming cells</u>

• Adenocarcinoma *

* Other common adenocarcinomas are found in the breast, colon, lung, prostate, uterus, sometimes cervix

- Other types of Ovarian Cancer start in the:
 - "eggs" (germ cell tumors)
 - body of the Ovary (stromal tumors)





Who develops Ovarian Adenocarcinoma?

• 15% Genetic Susceptibility known genetic susceptibility

- BRCA 1 / 2, HNPCC
- Lifetime risk up to 50% of developing Ovarian Cancer

•85% spontaneous somatic mutation

• Lifetime risk < 2% of developing Ovarian Cancer





How do we treat Ovarian Cancer?

- Current Approach -- Surgery and Chemotherapy
 - Primary Tumor Reductive Surgery (PDS)
 - Surgery → Chemotherapy
 - Neoadjuvant Chemotherapy (NACT)
 - Chemotherapy → Surgery → Chemotherapy
 - Goal of Surgery \rightarrow remove all visible disease
 - Goal of Chemotherapy \rightarrow kill all cancer cells






- The objectives of surgery in early stages are standardized and easy to meet
- In the recent years, survival of advanced ovarian cancer has substantially improved –
 - median overall survival 47 months
 - combination of chemotherapy and COMPLETE surgery





BACK TO BASICS



1- Why DEBULKING Surgery?

2- What is DEDULKING Surgery

3- Lymphadenectomy?


4- HIPEC?





1. Complete surgery is a mainstay of therapy


Every 10% increase of « optimal » surgery increases DFS by 2 months



NICE SANTA MARIA

1. Complete surgery is a mainstay of therapy

International Journal of Gynecological Cancer • Volume 22, Number 8, October 2012



527 French patients Consistent with literature





2. The issue of operative complications : the 2010 French survey

Patients

82% had neoadjuvant chemotherapy

Complete cytoreduction : 82%

Average duration of surgery : 270 minutes

Procedures :

- péritonectomy 81%
- bowel resection 68% including

55% sigmoidectomy

28% major upper abdominal surgery (splenectomy, pancreatectomy, full thickness

diaphragm resection, glissonectomy)





2. The issue of operative complications : the 2010 French survey

Results

Transitory colostomy 12%

Blood loss over 1000 ml 25% (94-3000)

```
Average ICU stay 4 days
Average hospital stay 10 days - 14% were still admitted at 30 days
```


45% had no complication40% had grade 1 or 2 complications.15% had grade 3 or more complications, including 2 deaths (1,6%).

10 reoperations (4 for bleeding, 6 for bowel complication)1 urinary fistula4 pulmonary embolisms








3. What is complete resection?





3. What is complete resection?





















4. Lymphadenectomy?


ORIGINAL ARTICLE

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms


P. Harter, J. Sehouli, D. Lorusso, A. Reuss, I. Vergote, C. Marth, J.-W. Kim,
F. Raspagliesi, B. Lampe, G. Aletti, W. Meier, D. Cibula, A. Mustea, S. Mahner,
I.B. Runnebaum, B. Schmalfeldt, A. Burges, R. Kimmig, G. Scambia, S. Greggi,
F. Hilpert, A. Hasenburg, P. Hillemanns, G. Giorda, I. von Leffern,
C. Schade-Brittinger, U. Wagner, and A. du Bois



	Lymphadenectomy Group	No-Lymphadenectomy Group
Characteristic	(N = 323)	(N = 324)
Median age (range) — yr	60 (21-83)	60 (23–78)
Median CA-125 level before surgery (IQR) — U/ml	416 (138–1276)	347 (122–1025)
ECOG performance status score — no. (%)†		
0	272 (84.2)	280 (86.4)
1	51 (15.8)	44 (13.6)
Histologic diagnosis available before registration — no. (%)	106 (32.8)	106 (32.7)
Final histologic diagnosis — no. (%)		
Ovarian, fallopian tube, or peritoneal cancer	306 (94.7)	307 (94.8)
Other diagnosis, including borderline tumor	17 (5.3)	17 (5.2)
Final FIGO stage — no. (%)‡		
I to IIA	15 (4.6)	17 (5.2)
IIB to IIIA	41 (12.7)	52 (16.0)
IIIB to IV∬	261 (80.8)	244 (75.3)
Missing data	6 (1.9)	11 (3.4)



B Progression-free Survival




No. at Risk Lymphadenectomy


No lymphadenectomy 323 282 239 324 303 256

 323
 282
 239
 183
 143
 120
 100
 89
 82
 65
 45
 31
 14
 6
 2
 0

 324
 303
 256
 193
 155
 133
 122
 109
 97
 78
 55
 33
 14
 5
 2
 2








5. Is Interval debulking surgery an acceptable option?


Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

Ignace Vergote, M.D., Ph.D., Claes G. Tropé, M.D., Ph.D., Frédéric Amant, M.D., Ph.D., Gunnar B. Kristensen, M.D., Ph.D., Tom Ehlen, M.D., Nick Johnson, M.D., René H.M. Verheijen, M.D., Ph.D., Maria E.L. van der Burg, M.D., Ph.D., Angel J. Lacave, M.D., Pierluigi Benedetti Panici, M.D., Ph.D., Gemma G. Kenter, M.D., Ph.D., Antonio Casado, M.D., Cesar Mendiola, M.D., Ph.D., Corneel Coens, M.Sc., Leen Verleye, M.D., Gavin C.E. Stuart, M.D., Sergio Pecorelli, M.D., Ph.D., and Nick S. Reed, M.D., for the European Organization for Research and Treatment of Cancer–Gynaecological Cancer Group and the NCIC Clinical Trials Group* — a Gynecologic Cancer Intergroup Collaboration

N Engl J Med 2010;363:943-53.



5. Is Interval debulking surgery an acceptable option?



International Journal of Gynecological Cancer • Volume 22, Number 8, October 2012





Unsolved issues

- (1) What is a « resectable » disease ?
 - There are technically no limits but retraction of the small bowel mesentery and massive involvement of most of small bowel length
 - In the real world, resecability is a trade-off between the objective of complete surgery and the risks of surgery
 - Postoperative mortality
 - Complication rate
 - Definitive alteration of quality of life






Unsolved issues

- (2) How to integrate intraperitoneal chemotherapy
 - Ample evidence that IP chemo improves the results however in patients with less than ideal surgery
 - Low acceptance in clinical practice
 - Competition with drug clinical trials





Van Driel et al NEJM 2018;378:230 Randomized study Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer



Panel A shows Kaplan-Meier estimates of recurrence-free survival among patients in the intention-to-treat population. Events of disease recurrence or death were observed in 110 patients (89%) in the surgery group and in 99 patients (81%) in the surgery-plus-HIPEC group. Panel B shows Kaplan-Meier estimates of overall survival among patients in the intention-to-treat population. A total of 76 patients (62%) in the surgery group and 61 (50%) patients in the surgery-plus-HIPEC group died.





J Clin Oncol. 2019 Jun 1;37(16):1380-1390. doi: 10.1200/JCO.18.01568. Epub 2019 Apr 19.

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Walker JL¹, Brady MF², Wenzel L³, Fleming GF⁴, Huang HQ², DiSilvestro PA⁵, Fujiwara K⁶, Alberts DS⁷, Zheng W⁸, Tewari KS³, Cohn DE⁹, Powell MA¹⁰, Van Le L¹¹, Davidson SA¹², Gray HJ¹³, Rose PG¹⁴, Aghajanian C¹⁵, Myers T¹⁶, Alvarez Secord A¹⁷, Rubin SC¹⁸, Mannel RS¹.

Author information

- 1 1 University of Oklahoma Health Sciences Center, Oklahoma City, OK.
- 2 2 Roswell Park Cancer Institute, Buffalo, NY.
- 3 3 University of California, Irvine, Medical Center, Orange, CA.
- 4 4 The University of Chicago Medicine, Chicago, IL.
- 5 5 Women and Infants Hospital, Providence, RI.
- 6 6 Saitama Medical University International Medical Center, Hidaka-Shi, Japan.
- 7 7 The University of Arizona Cancer Center, Tucson, AZ.
- 8 8 The University of Arizona, Tucson, AZ.
- 9 9 The Ohio State University, Columbus, OH.
- 10 10 Washington University in St Louis, St Louis, MO.
- 11 11 University of North Carolina at Chapel Hill, Chapel Hill, NC.
- 12 12 University of Colorado, Aurora, CO.
- 13 13 University of Washington School of Medicine, Seattle, WA.
- 14 14 Cleveland Clinic Foundation, Cleveland, OH.
- 15 15 Memorial Sloan Kettering Cancer Center, New York, NY.
- 16 16 University of Connecticut, Storrs, CT.
- 17 17 Duke University Health System, Durham, NC.
- 18 University of Pennsylvania, Philadelphia, PA.





Advanced Ovarian cancer surgery : take home messages

- The 0 residue is the target
- Can be achieved in 80% of patients
- Can be completed as primary treatment or after neoadjuvant chemotherapy
- Involves major visceral surgery if the overall estimated risk is acceptable
- No surgeon should undertake such a surgery without the skills to perform en bloc radical oophorectomy and upper abdominal procedures



